
NICE has issued Final Draft Guidance recommending AbbVie’s AQUIPTA (atogepant) as an option for the acute treatment of migraine, with …

AbbVie has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for Aquipta (atogepant), …

Allergan has made ground in its quest to become “the headache company” with the release of new Phase 2b/3 data …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations

